<DOC>
	<DOCNO>NCT01177735</DOCNO>
	<brief_summary>This phase II study , open-label , single institution trial pomalidomide GEP-defined , high-risk relapsing/refractory multiple myeloma . Prior therapy must include lenalidomide . Patient accrual 30 2 year period . Primary objective : - To determine progression-free survival ( PFS ) initiation pomalidomide therapy Secondary objective : - To determine response rate ( CR , n-CR , VGPR ) duration response pomalidomide therapy . - To determine gene expression profile ( GEP ) change exert within 48 hour initiation daily pomalidomide dose . - To determine gene expression profile ( GEP ) change exert within 48 hour initiation 3 concurrent day exposure lenalidomide . - To determine MRI- PET-CT-defined CR study obtain baseline every 6 month examination .</brief_summary>
	<brief_title>Pomalidomide Gene Expression Profiling ( GEP ) -Defined High-risk Multiple Myeloma</brief_title>
	<detailed_description>Pomalidomide 2nd generation immunomodulatory agent ( IMiD® ) great efficacy lenalidomide similar toxicity spectrum . Phase I trials show pomalidomide 1 5 mg well-tolerated1,2 . TT3 remarkably successful management newly diagnose MM , induce CR rate &gt; 60 % 4-year estimate overall event-free survival 85 % 75 % . Of achieve CR , estimate 4-year CR rate 85 % . TT3 maintenance either VTD 2003-33 VRD 2006-66 , pomalidomide 's role overcome refractoriness lenalidomide assess . Pharmacogenomic investigation compare GEP data obtain baseline 48hr post-treatment perform case thalidomide , dexamethasone , lenalidomide , bortezomib melphalan3 . Thus , patient TT3 baseline 48-hr GEP investigation perform bortezomib , opportunity exists investigate , time relapse , re-challenge bortezomib 48hr GEP also pomalidomide 's effect . This phase II study , open-label , single institution trial pomalidomide GEP-defined , high-risk relapsing/refractory multiple myeloma . Prior therapy must include lenalidomide .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Participant multiple myeloma , relapse resistant prior therapy . Participant highrisk disease , define follow : GEP risk score &gt; 0.66 OR Metaphase base abnormality 1q 1p OR LDH &gt; 360 U/L Participant receive prior therapy lenalidomidecontaining regimen determine refractory , resistant , relapse . Participant significant peripheral neuropathy ( &lt; grade 3 current NCI CTCAE version ) Participant adequate hematopoietic reserve define platelet count ≥ 50,000/µL ANC &gt; 1000/µL . Participant adequate renal function define serum creatinine &lt; 2 mg/dL . Participant adequate hepatic function , define serum Total bilirubin &lt; /= 1.5 mg/dL AST ( SGOT ) ALT ( SGPT ) &lt; /= x ULN . Participant 18 year age great . Participant receive anticancer therapy within 4 week prior treatment study . Zubrod ≤ 2 , unless solely due symptom MMrelated bone disease . Disease free prior malignancy &gt; /= 5 year exception currently treat basal cell , squamous cell carcinoma skin , carcinoma situ cervix breast . Females childbearing potential ( FCBP ) † must negative serum urine pregnancy test sensitivity least 25 mIU/mL within 10 14 day prior within 24 hour prior start lenalidomide CC4047 must either commit continue abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 28 day start take lenalidomide CC4047 . All patient must inform investigational nature study must sign give write voluntary consent accordance institutional federal guideline . Willing able take aspirin alternate prophylactic anticoagulation . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . Pregnant breast feeding female . Men unwilling use condom ( even undergone prior vasectomy ) intercourse woman , take drug 4 week stop treatment . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . Use experimental drug therapy within 28 day baseline . Known hypersensitivity lenalidomide . The development erythema nodosum characterize desquamate rash take lenalidomide , CC4047 similar drug . Any prior use CC4047 . Concurrent use anticancer agent treatment . Known seropositive active viral infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) . Patients seropositive hepatitis B virus vaccine eligible . Active malignancy ( exception non melanoma skin cancer situ cervical breast cancer ) . Active DVT PE therapeutically anticoagulated . ≥ grade 3 peripheral neuropathy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Pomalidomide</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>relapse</keyword>
</DOC>